Articles tagged "Adverse effects"

2022 American Transplant Congress
Impact Of Nirmatrelvir-Ritonavir On Tacrolimus Concentrations
S. Fredrick¹, B. Wise², L. Bowman², D. DeWolfe¹, J. Taylor¹, J. Melaragno¹
¹University of Rochester Medical Center, Rochester, NY, ²Tampa General Hospital, Tampa, FL
*Purpose: Ritonavir (RTV), a component of the oral antiviral agent nirmatrelvir-RTV (Paxlovid) for COVID-19 infection, increases tacrolimus concentrations through strong competitive inhibition of gastrointestinal and…
2022 American Transplant Congress
Clinical Outcomes with IR-tac to LCP-tac Conversion in a Kidney Transplant Population
F. Bartlett¹, J. Newman¹, T. Sprague¹, S. Patel¹, N. Rao², E. Andrade², V. Rohan², M. Casey², D. Dubay¹, D. Taber¹
¹Pharmacy, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC
*Purpose: LCP-Tac is approved for conversion from IR-Tac in kidney transplant patients with a conversion rate of 70-80%. Studies have demonstrated similar efficacy and safety…
2022 American Transplant Congress
Incidence and Risk Factors Associated with the Development of Hypoglycemia After Combined Pancreas-Kidney Transplantation
S. Kapoor¹, S. Jain², S. Stefan³, Y. Azzi³, M. Ajaimy³, P. Loarte-Campos³, C. Pynadath³, H. C. Yaffe³, M. Le³, J. Rocca³, S. Greenstein³, M. Kinkhabwala³, J. Graham³, E. Akalin⁴, L. Liriano-Ward³
¹Montefiore Medical Center, New York, NY, ²Montefiore Medical Center, Scarsdale, NY, ³Montefiore Medical Center, Bronx, NY, ⁴Albert Einstein College of Medicine, Montefiore Medical Ctr, Bronx, NY
*Purpose: To review the incidence of hypoglycemia after pancreas transplantation in recipients with type 1 and 2 diabetes mellitus and the risk factors associated with…
2022 American Transplant Congress
Evaluation of Conversion from Immediate Release (IR) Tacrolimus to LCP-Tacrolimus (Envarsus XR®, LCP) in Heart Transplant Recipients
E. Foster¹, A. Iaria¹, J. Negrelli², M. Fine², M. Yu², M. Liebo²
¹University of Illinois at Chicago, Chicago, IL, ²Loyola University Medical Center, Maywood, IL
*Purpose: The purpose of this study was to assess outcomes in heart transplant recipients who were converted from IR tacrolimus to LCPT. Limited data exists…
2022 American Transplant Congress
Outcome Predictors with Perioperative Kidney Transplant Midodrine Usage
R. Watson¹, S. Mullins², S. Williams³, F. Fakhre⁴, K. Robichaux⁴, S. Mohammed⁴, M. Gosselin³, A. Kumar⁵, J. Buggs¹, V. Bowers¹
¹Transplant Surgery, Tampa General Hospital, Tampa, FL, ²Florida A &M University, Tallahassee, FL, ³University of Tampa, Tampa, FL, ⁴University of South Florida, Tampa, FL, ⁵Morsani College of Medicine, University of South Florida, Tampa, FL
*Purpose: Midodrine is an alpha-1 agonist drug commonly used to aid hypotension in kidney transplant patients. Little is described regarding outcomes with midodrine in kidney…
2022 American Transplant Congress
Longitudinal Analysis of the Gut Microbiota Structure and Function After Renal Transplantation
A. Vaitkute¹, F. Yuen Chang¹, A. Greco², S. Chong¹, H. Mahdi³, M. Bajaj-Elliott², A. Pesenacker¹, R. Motallebzadeh¹
¹Institute of Immunity and Transplantation, UCL, London, United Kingdom, ²Institute of Child Health, UCL, London, United Kingdom, ³Department of Renal Medicine, UCL, London, United Kingdom
*Purpose: Despite marked improvements in outcomes after renal transplantation, graft loss from alloimmune pathology and adverse side effects including urinary tract infections and diarrhoea remain…
2022 American Transplant Congress
Development of a Patient-Reported Outcome Measure of Neurological Side Effects from Immunosuppression in Kidney Transplant Recipients
C. Hurt¹, G. J. Greene¹, J. Friedewald², D. P. Ladner², A. Waterman³, D. Cella¹, D. Peipert¹
¹Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, ²Department of Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL, ³Department of Surgery and J.C. Walter Jr. Transplant Center, Houston Methodist Hospital, Houston, TX
*Purpose: Though kidney transplant is the optimal treatment for most individuals with end stage kidney disease, recipients experience significant side effects associated with their required…
2022 American Transplant Congress
Impact of Dysgeusia on Transplant Recipients with Refractory Cytomegalovirus with/without Resistance Receiving Maribavir: Post-Hoc Analyses from a Phase 3 Randomized Trial
F. Silveira¹, S. Haider², D. Kaul³, O. Witzke⁴, J. Gu⁵, A. Sundberg⁵
¹Univ. Pittsburgh, Pittsburgh, PA, ²McMaster Univ., Hamilton, ON, Canada, ³Univ. Michigan, Ann Arbor, MI, ⁴Univ. Duisburg-Essen, Essen, Germany, ⁵Takeda Development Center Americas, Inc., Lexington, MA
*Purpose: In a Phase 3 study (SOLSTICE; NCT02931539), maribavir (MBV) was superior to investigator-assigned therapies (IAT; val/ganciclovir, foscarnet, or cidofovir) for CMV clearance at Wk…
2022 American Transplant Congress
The Impact of Long-Term Exposure to Tacrolimus on Chronic Kidney Disease Following Lung Transplantation: A Retrospective Analysis from a Single Transplantation Center
D. Xiong, J. Zhang, J. Chen
Lung Transplantation Center, Department of Thoracic Surgery, Wuxi People’s Hospital Affiliated to Nanjing Medical Univer, Wuxi, China
*Purpose: Chronic kidney disease (CKD) is a progressive and irreversible complication in lung transplant patients who have received long-term treatment with tacrolimus. This study aimed…
2022 American Transplant Congress
The Sustained Impact of a Minimization Protocol on Peri-Operative Opioid Use in Kidney Transplantation
N. Patel, T. Carcella, J. Marable, V. Rohan, S. Bethi, P. Baliga, D. Dubay, J. N. Fleming, D. Taber
-MUSC, -Charleston, SC
*Purpose: Opioid use following kidney transplant (KTX) is associated with higher graft and patient loss. Thus, in 2019 we implemented an opioid minimization quality improvement…

1
2
3
…
18
Next Page »